Croma-Pharma GmbH Enters Strategic Distribution Partnership with Renellence in Canada

Leobendorf, Austria / Toronto, Canada – October 10, 2025 – Croma-Pharma
GmbH, a global leader in minimally invasive aesthetic medicine, today
announced a new distribution partnership with Renellence, a Canadian
company specializing in aesthetic medicine. This strategic collaboration
strengthens Croma’s presence in the Canadian market and builds upon the
company’s long-standing heritage in the region.

Under the agreement, Renellence will distribute the MDR-approved (Medical
Device Regulation) hyaluronic acid filler range Croma saypha® in Canada,
further expanding access to Croma’s science-driven, high-quality aesthetic
solutions. The partnership reflects a shared commitment to innovation,
excellence, and customer-focused service, laying the foundation for
sustainable long-term growth.

“Canada has always been an important market for Croma-Pharma, and we
are proud of the foundation we have established here over the years,” said
Andreas Prinz, Chief Executive Officer of Croma-Pharma GmbH. “Partnering
with Renellence allows us to combine Croma’s global expertise with their strong
local market knowledge and network, positioning us for continued success in
Canada.”

The partnership will also focus on strengthening medical education and training
initiatives for Canadian healthcare professionals, supporting safe and effective
patient outcomes across the country.

Aria Moghimi, Chief Executive Officer of Renellence, stated, "Croma is
recognized worldwide for quality and safety, and Saypha embodies both. This
partnership positions Renellence to play a defining role in shaping the future
of aesthetics in Canada, and we are proud to lead that transformation
together with Croma."

About Croma-Pharma GmbH

Croma-Pharma GmbH is a family-owned global player in the minimally invasive
aesthetics market, headquartered in Leobendorf, Austria. The company
specializes in the industrial production of hyaluronic acid syringes and
distributes its own aesthetic portfolio, including botulinum toxin, fillers, PDO
threads, PRP, and skincare technologies, in more than 80 markets worldwide.

About Renellence

Renellence Inc. is a Canadian aesthetics company dedicated to bringing
scientifically proven and clinically safe innovations to the medical aesthetics
market. With a focus on products that meet the highest international standards,
Renellence serves as a platform for advancing innovation and delivering
trusted solutions to Canadian practitioners. The company’s mission is to
connect global breakthroughs with local clinical practice, improving patient
outcomes while driving the growth of the aesthetics industry.